Angiodynamics released FY2025 Q2 earnings on January 8 Pre-Market (EST), actual revenue $72.85M (forecast $70.93M), actual EPS -$0.2624 (forecast -$0.22)

Brief Summary

AngioDynamics reported Q2 2025 revenue of $72.85 million, exceeding expectations of $70.93 million, but an EPS of -$0.2624 fell short of the expected -$0.22.

Impact of The News

Financial Performance Overview:

• Revenue: AngioDynamics’ Q2 2025 revenue was $72.85 million, which surpassed market expectations of $70.93 million, reflecting a positive deviation from analysts’ forecasts Market Beat+ 2. However, it also represented a year-over-year decline of 8%, indicating challenges in maintaining revenue growth Alpha Street.
• Earnings Per Share (EPS): The company reported an EPS of -$0.2624, missing the consensus estimate of -$0.22. This suggests that while revenue performance was strong, cost management or other financial factors led to a larger-than-anticipated net loss Market Beat.

Market Position and Expectations:

• Market Comparison: Despite missing EPS expectations, the company’s financial guidance remains more optimistic than previous forecasts. AngioDynamics revised its FY2025 EPS guidance to a range of -$0.34 to -$0.38, better than prior expectations of -$0.38 to -$0.42 Market Beat.
• Revenue Guidance: The company maintains its FY2025 revenue guidance at $282 to $288 million, consistent with earlier estimates and suggesting moderate growth from $270.7 million in FY2024 .

Business Status and Future Outlook:

• Current Challenges: The decline in revenue and missing EPS expectations indicate operational or market-related hurdles. Special project costs or market dynamics could be influencing the company’s profitability Alpha Street.
• Future Prospects: Given the raised financial guidance and positive market reception (with the stock price increasing by 25% presumably due to the improved guidance), AngioDynamics is positioning itself for recovery and potential growth. This could signal strategic initiatives to address current financial shortcomings and capitalize on market opportunities Benzinga.